Starpharma Holdings Limited is a world leader in the development of dendrimer products for pharmaceutical, life-science and other applications.

Starpharma’s lead sexual health product under development is VivaGel^® (SPL7013 Gel), a vaginal microbicide to prevent the transmission of sexually transmitted infections (STIs) including HIV and genital herpes; and also for treatment and prevention of bacterial vaginosis (BV). VivaGel^® as a condom coating has been licensed with Ansell and Okamoto.

In the wider pharmaceutical and life science fields, Starpharma has specific programs in dendrimer drug delivery, including drug targeting, drug solubilisation, diagnostics and pharmaceutical excipients.

More broadly, Starpharma is exploring dendrimer opportunities in agrochemicals, cosmetics and materials science with applications as diverse as paints, coatings, adhesives, and water remediation.